The role of alpha-glucosidase inhibitors (Acarbose)

Pharmacotherapy of Diabetes: New Developments: Improving Life and Prognosis for Diabetic Patients

Volumn , Issue , 2007, Pages 143-152

  Hanefeld, Markolf ^a   Schaper, Frank ^a  

^a Center for Clinical Studies   (Germany)

Author keywords

acarbose; cardiovascular disease; diabetes; metabolic syndrome; pharmacology; primary prevention

Indexed keywords

EID: 48349139662     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69737-6_13     Document Type: Chapter

References (57)

1. Wallander M, Bartnik M, Efendic S et al. Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study. Diabetologia 2005;48(11):2229-2235.
2. Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: The Diabetes Intervention Study, 11 years follow-up. Diabetologia 1996;39(12):1577-1583.
3. Ceriello A, Hanefeld M, Leiter L et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164(19):2090-2095.
4. Burchfiel CM, Curb JD, Rodriguez BL et al. Glucose intolerance and 22-year stroke incidence. The Honolulu Heart Program. Stroke 1994;25(5): 951-957.
5. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26(3):688-696.
6. Kawano H, Motoyama T, Hirashima O et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999;34(1):146-154.
7. Scognamiglio R, Negut C, De Kreutzenberg SV et al. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005; 112(2):179-184.
8. Rudofsky G, Reismann P, Schiekofer S et al. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-κB activation in PBMCs. Horm Met Res 2004;36:630-638.
9. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295(14):1681-1687.
10. Woerle HJ, Szoke E, Meyer C et al. Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab 2006; 290(1):E67-E77.
11. Coutinho M, Gerstein HC, Wang Y et al. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22(2):233-240.
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853.
13. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355(23): 2427-2443.
14. Salsburg DS. The UGDP study. JAMA 1971;218(11):1704-1705
15. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355(23):2427-2443.
16. Salsburg DS. The UGDP study. JAMA 1971;218(11):1704-1705.
17. Goke B, Herrmann C, Goke R et al. Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest 1994;24(Suppl 3):25-30.
18. Puls W. Pharmacology of glucosidase inhibitors. Oral Antidiabetics. Berlin: Springer, 1996;119:497-525.
19. Puls W, Keup U, Krause HP et al. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity and hyperlipoproteinemia. Naturwissenschaften 1977;64:536-537
20. Puls W, Keup U, Krause HP et al. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity and hyperlipoproteinemia. Naturwissenschaften 1977;64:536-537.
21. Schmidt DD, Frommer W, Junge B et al. Alphaglucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften 1977;64: 535-536.
22. Krause HP, Ahr HJ. Pharmacokinetics and metabolism of glucosidase inhibitors. In: Kuhlmann J, Puls W, editors. Handbook of Experimental Pharma-cology: Oral Antidiabetics. Vol. 119. Berlin: Springer, 1996;541-545.
23. Junge B, Matzke M, Stoltefuss J. Chemistry and structure- activity relationships of glucosidase inhibitors. In: Kuhlmann J, Puls W, editors. Handbook of Experimental Pharmacology: Oral Antidiabetics. Vol. 119. Berlin: Springer, 1996;541-545.
24. Joubert PH, Venter HL, Foukaridis GN. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism. Br J Clin Pharmacol 1990;30:391-396.
25. Toeller M. Modulation of intestinal glucose absorption: postponement of glucose absorption by alphaglucosidase inhibitors. In: Mogensen CE, Standl E, editors. Pharmacology of Diabetes. Berlin: De Gruyter, 1991;93-112.
26. Meneilly G, Ryan EA, Radziuk J et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000;23:1162-1167.
27. Hillebrand I, Boehme K, Frank G et al. Effects of the glycoside hydrolase inhibitor (BAY g 5421) on postprandial blood glucose, serum insulin and triglycerides levels in man. In: Creutzfeldt W, editor. Frontiers of Hormone Research, the Entero-insular Axis. Basel: Karger, 1979; 7: 290-291.
28. Hanefeld M, Fischer S, Schulze J et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14:732-737.
29. Chiasson JL, Josse RG, Leiter LA et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996;19:1190-1193.
30. Laube H, Linn T, Heyen P. The effects of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998;106:231-233.
31. Hanefeld M, Haffner SM, Menschikowski M et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes. Diabetes Res Clin Pract 2002;55:221-227.
32. Chiasson JL, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. Lancet 2002;359(9323): 2072-2077.
33. Goke B, Fuder H, Wieckhorst G et al. Voglibose is an efficient alpha-glucosidase inhibitor and mobilize the endogenous GLP-1 reserve. Digestion 1995;56: 493-501
34. Qualmann C, Nauck MA, Hoist JJ et al. Glucagonlike peptide 1 (GLP-1) [17-36 amide] secretion in response to luminal sucrose from the upper and lower gut: a study using α-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995;30:892-896.
35. Holman RR, Turner RC, Cull CA et al. A randomised double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999;22:960-964.
36. Wolever TMS, Chiasson JL, Josse RG et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord 1997;21:756-763.
37. Lindström J, Tuomilehto J, Spengler M. Acarbose treatment does not change the habitual diet of patients with type 2 diabetes mellitus. The Finnish Acarbose Study Group. Diabet Med 2000;17(1):20-25.
38. Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Invest 2002;22(10):695-701.
39. Hanefeld M, Cagatay M, Petrowitsch T et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25(1):10-16.
40. Wascher TC, Schmoelzer I, Wiegratz A et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005;35(9):551-557.
41. Leonhardt W, Hanefeld M, Fischer S et al. Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. Eur J Clin Invest 1994;24(Suppl 3):45-49.
42. Inoue I, Shinoda Y, Nakano T et al. Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metabolism 2006;55(7):946-952.
43. Hanefeld M, Fischer S, Schulze J et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991;14:732-737.
44. Heine RJ, Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002;45(4):461-475.
45. Tschoepe D. Decreased fibrinogen by treatment with the alpha-glucosidase inhibitor acarbose. Diabetes 2004;53(Suppl 2):A189.
46. Wang X, Lu J, Pan C. Comparison of serum C-reactive protein level in different glucose tolerance subjects and the change in serum CRP level in IGT subjects with acarbose. EASD 2003. Published in Chinese: Lu JM et al. Chin J Endocrinol Metab 2003;19:254-256.
47. Drent ML. Miglitol as single oral hypoglycemic agent in type 2 diabetes [Abstract]. Diabetologia 1994;37(Suppl 1):211.
48. Mertes G. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from 5-year surveillance study. Diabetes Res Clin Pract 2001;2:193-204.
49. Leboritz HE. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998;6:132-145.
50. Hanefeld M, Fischer S, Julius U et al. and the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583.
51. Temelkova-Kurktschiev T, Kohler C, Henkel E, et al. Post-challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbAlc level. Diabetes Care 2000; 23: 1830-1834.
52. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26(3):881-885.
53. May C. Efficacy and tolerability of step wise increasing dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM) treated with sulfonylureas. Diabetes Stoffwechsel 1995;4:3-7.
54. Fischer S, Hanefeld M, Spengler M, et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. 1998; 35:34.
55. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
56. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290(4): 486-494.
57. Hanefeld M, Chiasson JL, Koehler C et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35(5):1073-1078.